Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PBMs

- PMLiVE

Democrats in the US agree plan to curb drug prices

House Democrats have added a measure to curb prescription drug costs to President Biden’s $1.85tr social safety net plan

- PMLiVE

White House unveils plans to reimport medicines from Canada

Unthinkable to previous administrations, but scepticism rife amid flurry of policy ideas

- PMLiVE

PhRMA opposed to Senate drug price control plans

But has bipartisan support and Trump backing

- PMLiVE

Another setback on pricing as Trump drops rebate plans

Follows pharma's blocking of advertising changes

- PMLiVE

Trump presses on with reference pricing plan for medicines

Proposed pilot programme to run until 2025

- PMLiVE

Countries hail ‘landmark’ drug pricing transparency resolution, despite watering down

US among those in favour of price transparency

- PMLiVE

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Insulin price nearly tripled between 2002 and 2013

- PMLiVE

Tit for tat as PBMs blame pharma for high drug prices

US Senate turns its spotlight on 'middlemen'

- PMLiVE

Gottlieb signs off with flair – and pledge of further drug price commentary

Highlights issues of insulin prices and competition

- PMLiVE

Trump budget targets rebates, out-of-pocket costs

Biotech sector welcomes end to rebates, but worries about Medicare cuts

- PMLiVE

Senate grilling makes pharma CEOs squirm, but give little ground

Some signal willingness to compromise, but oppose most radical reforms

- PMLiVE

Fireworks likely at Senate drug pricing hearing today

Senators fire broadsides: "I hope CEOs don't blame everyone but themselves"

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links